Trikatu is the classical “three pungents” combination of Maricha (black pepper, Piper nigrum fruit), Pippali (long pepper, Piper longum fruit), and Shunthi (dry ginger, Zingiber officinale rhizome), traditionally prepared in equal parts. In Ayurveda it is used as a deepana-pachana formulation: it supports appetite, kindles agni, helps digest ama, and is especially suited to kapha-dominant sluggishness, heaviness, coldness, and mucus tendency.

Modern pharmacokinetic work gives a useful explanation for one reason Trikatu became famous as a yogavahi-style helper in formulations: its pepper components contain piperine, and piperine can alter intestinal absorption and first-pass handling of some substances. This makes Trikatu valuable, but it also means it should not be treated as an ordinary kitchen spice when used in concentrated doses or alongside medicines with narrow safety margins.

Mechanism of Bioavailability Enhancement: Three Main Pathways

Piperine is the principal pungent alkaloid of black pepper and is also present in long pepper. It has been characterized as an inhibitor of human P-glycoprotein and CYP3A4, two systems that strongly influence oral drug disposition. P-glycoprotein can pump absorbed compounds back toward the intestinal lumen, while CYP3A4 contributes to intestinal and hepatic metabolism of many medicines and phytochemicals. Piperine also acts on TRPV1, the pungency-sensing ion channel associated with the “hot” sensory action of pepper.

For curcumin, a classic human pharmacokinetic trial found that 20 mg piperine given with 2 g curcumin markedly increased measurable curcumin exposure. This finding is often used to explain why pepper extracts are added to turmeric and curcumin products. The same principle should be handled carefully: a substance that increases exposure to one poorly absorbed compound may also alter exposure to selected medicines.

Current Drug-Interaction Perspective

The practical issue is not that every pinch of pepper creates a drug interaction. The concern is concentrated piperine, repeated use, extract-strength products, or Trikatu used medicinally in people taking medicines affected by CYP3A4, P-glycoprotein, CYP2C9, or clotting pathways. Human and modeling data indicate that piperine-containing preparations can affect selected probe drugs and CYP3A4-substrate exposure, while not every clinical experiment shows a large effect under every dosing condition. For household culinary use the concern is lower; for therapeutic churna, capsules, or standardized piperine extracts the concern is higher.

Trikatu’s Three Components Are Not Interchangeable

Black pepper extract is not the same as classical Trikatu. Maricha supplies piperine-rich pungency and strong kapha-vata-reducing heat. Pippali adds a related but distinct long-pepper profile, traditionally valued in kasa, shvasa, agnimandya, and rasayana contexts when used properly. Shunthi brings the dry-ginger action: warming, digestive, kapha-vata-pacifying, and more suitable than fresh ginger in many kapha-ama patterns.

The phytochemical profile also differs. Long pepper contains piperine and other amide constituents, including piperlongumine, a compound investigated mainly in preclinical pharmacology. Dry ginger contains gingerols and shogaols, with shogaols becoming more prominent in dried or heated ginger. Classical Trikatu should therefore be understood as a three-drug formulation, not merely as “piperine powder.”

Ayurvedic Use: Deepana, Pachana, Kapha-Vata Support

In Ayurvedic practice, Trikatu is best matched to cold, heavy, sluggish digestion; coated tongue with ama tendency; reduced appetite; kapha-type congestion; and vata-kapha obstruction where warmth, sharpness, and scraping action are desired. Its katu rasa, ushna tendency, and tikshna quality make it inappropriate for many pitta-dominant presentations unless carefully balanced by an experienced practitioner.

Its role in formulas is also important. Trikatu appears widely as a supporting combination because it can sharpen the digestive and assimilative action of a preparation. This is the classical counterpart to its modern bioenhancer reputation: it is not only a “pepper additive,” but a digestive-fire correcting group that changes how a formulation is received by the body.

Dosage Guidance and Practical Use

Common adult churna use is conservative, often around 500 mg to 1.5 g once or twice daily, usually with honey, warm water, or as directed by a qualified Ayurvedic practitioner. Sensitive individuals may require smaller amounts, and those with heat, acidity, gastritis, ulcers, loose stools with burning, or bleeding tendency may not be suitable candidates.

For deliberate nutraceutical bioavailability enhancement, standardized piperine doses in the 5-20 mg range appear in human trials and product practice, but that is not automatically equivalent to taking classical Trikatu. Trikatu contains three botanicals with their own actions, and its use should be based on agni, dosha, disease state, season, strength, and concurrent medicines.

For respiratory or kapha-metabolic use, Trikatu is traditionally paired with honey or warm water when kapha is prominent. Higher or repeated dosing is more likely to provoke pitta symptoms and more likely to raise interaction concerns. A short, practitioner-guided course is preferable to long unsupervised daily use.

Contraindications and Special Populations

Trikatu should generally be avoided in active peptic ulcer disease, significant acid reflux with burning, inflammatory bowel flare, bleeding tendency, marked pitta aggravation, and unexplained abdominal pain. It may cause burning, throat irritation, sweating, loose stools, or heat symptoms when the dose or patient selection is wrong.

Pregnant women should not use medicinal Trikatu unless specifically prescribed by a qualified clinician. People who are breastfeeding, elderly, taking long-term prescription medicines, preparing for surgery, using anticoagulants or antiplatelet drugs, or living with liver, kidney, transplant, seizure, cardiac, or autoimmune conditions should consult a qualified practitioner or healthcare provider before using Trikatu medicinally.

Medical disclaimer: This content is for educational purposes only and does not constitute medical advice. Trikatu and piperine-containing products may interact with medicines. Consult a qualified Ayurvedic practitioner, physician, or pharmacist before using Trikatu therapeutically, especially if you take prescription medicines or have a diagnosed medical condition.

References

1. Ijrap (ijrap.net)
2. Ayurvedic Pharmacopoeia of India
3. Ayurvedic Pharmacopoeia of India
4. Pubchem (pubchem.ncbi.nlm.nih.gov)
5. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 (2002), PubMed
6. A distinct structural mechanism underlies TRPV1 activation by piperine (2019), PubMed Central
7. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers (1998), PubMed
8. Hero (hero.epa.gov)
9. The effect of piperine on midazolam plasma concentration in healthy volunteers, a research on the CYP3A-involving metabolism (2014), PubMed Central
10. Mdpi (mdpi.com)
11. FDA
12. FDA
13. Effects of Oral Ginger Supplementation on the INR (2019), PubMed Central
14. Health (health.ucsd.edu)
15. Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent (2020), PubMed
16. NCBI
17. 1mg (1mg.com)
18. Easyayurveda (easyayurveda.com)

Trikatu, literally “three pungents,” is the classical combination of Maricha (black pepper), Pippali (long pepper), and Shunthi (dry ginger). It is valued in Ayurveda because its pungent, warming, and penetrating qualities support dipana (kindling of digestive fire), pachana (digestion of ama), kapha reduction, and the movement of sluggish vata-kapha states. Those same qualities also mean that Trikatu should not be treated as a casual daily spice capsule, especially when a person has acidity, bleeding risk, pregnancy, or prescription medication use.

This safety profile keeps Trikatu’s traditional role intact while setting clear limits around modern use. The main concerns are piperine-related drug interactions, pitta and gastric aggravation, additive effects from the ginger component, and the need to keep dosing within a defined therapeutic context.

The Three Components in Classical Ayurvedic Terms

Trikatu is not one herb but a concentrated three-drug compound. Each ingredient contributes pungency and digestive action, but the official Ayurvedic monographs describe distinct identities, properties, and dose ranges for the individual drugs.

Why Trikatu Works and Why It Needs Boundaries

The Ayurvedic logic of Trikatu is straightforward: pungent, warming, sharp, and light qualities counter cold, heavy, sticky, and sluggish kapha-vata patterns. This is why Trikatu is traditionally useful in mandagni, ama-related heaviness, kapha-type congestion, and sluggish digestion. The safety issue is that a medicine designed to be ushna and tikshna can aggravate burning, reflux, ulcers, bleeding tendency, and pitta-dominant symptoms when used in the wrong person, at the wrong dose, or for too long.

Modern pharmacology adds another boundary. Maricha and Pippali contain piperine and related alkaloids. Piperine can affect intestinal and hepatic systems involved in drug transport and metabolism, especially P-glycoprotein and CYP3A4, and it has also produced clinically relevant changes with medicines such as phenytoin, carbamazepine, propranolol, and theophylline. This is the central reason Trikatu should be handled carefully in people taking regular medication.

Drug Interaction Concerns

The interaction concern with Trikatu is not merely theoretical. Piperine can change the exposure of co-administered substances, which may be desirable when enhancing the absorption of a selected herb but risky when the co-administered substance is a prescription drug with a narrow safety range.

Gastric and Pitta-Aggravating Effects

Trikatu’s pungent and heating nature is therapeutically useful when digestion is cold, heavy, and sluggish. In a person with burning acidity, inflamed gastric mucosa, sour reflux, mouth ulcers, or pitta aggravation, the same qualities can become irritating. Piperine has increased gastric acid secretion in animal models and has also altered gastric emptying and intestinal transit, so Trikatu should not be assumed to be gentle simply because it is a classical formulation.

• Active gastritis, peptic ulcer, or severe reflux: Avoid self-use because pungent, ushna, and tikshna drugs may intensify burning, sour belching, epigastric discomfort, or reflux symptoms.
• Chronic NSAID use: People taking ibuprofen, diclofenac, naproxen, aspirin, or similar drugs already require gastric caution; adding Trikatu should be done only with professional guidance.
• Pitta-dominant symptoms: Burning stools, mouth ulcers, excessive heat, irritability with acidity, nosebleeds, or inflamed skin conditions are signs to avoid casual heating formulations.
• Empty-stomach use: Taking Trikatu on an empty stomach can be more irritating; when appropriate, it is generally better tolerated after food or with a suitable anupana chosen by a practitioner.

The Piperine Paradox

Piperine is useful precisely because it can increase exposure to selected co-administered compounds. A small human pharmacokinetic comparison found that adding 20 mg piperine greatly increased measured curcumin exposure. This is why piperine-containing combinations are popular in turmeric and herbal bioavailability products.

The same mechanism becomes a safety concern when the co-administered substance is a pharmaceutical drug. Enhancing curcumin exposure may be the intended design of a formula; enhancing phenytoin, carbamazepine, theophylline, propranolol, tacrolimus, cyclosporine, warfarin, or certain statins may be unsafe. Trikatu is therefore not “good” or “bad” in isolation. Its safety depends on the patient, the dose, the duration, and everything else being taken with it.

The Shunthi Component: Separate Considerations

Shunthi gives Trikatu important digestive, anulomana, and vata-kapha balancing value, but it is not pharmacologically inert. Concentrated ginger preparations deserve caution in people taking anticoagulants, antiplatelet drugs, diabetes medicines, or multiple cardiovascular medicines.

• Bleeding-risk medication: Use caution with aspirin, clopidogrel, warfarin, direct oral anticoagulants, and similar medicines.
• Blood sugar medication: People using insulin or sulfonylureas should monitor glucose carefully if any concentrated ginger-containing formulation is added.
• Reflux-prone patients: Even though ginger is often used for nausea and digestion, dry ginger in Trikatu is heating and may not suit people whose main complaint is burning reflux.

Who Should Avoid Trikatu or Use It Only With Supervision

Trikatu is most appropriate for cold, heavy, kapha-vata digestion under the right conditions. The following groups should avoid self-prescribed use or take it only after review by a qualified Ayurvedic practitioner and, when medicines are involved, a physician or pharmacist.

• People taking narrow-therapeutic-index medicines: This includes phenytoin, carbamazepine, theophylline, digoxin, warfarin, cyclosporine, tacrolimus, and similar medicines where small exposure changes matter.
• People taking multiple long-term medicines: Polypharmacy increases the chance that one drug is affected by CYP3A4, CYP2C9, or P-glycoprotein pathways.
• People with active gastritis, peptic ulcer disease, severe GERD, or burning acidity: Trikatu’s ushna and tikshna nature can be unsuitable in these states.
• People with bleeding disorders or planned surgery: Avoid unsupervised use, especially when anticoagulants, antiplatelets, or NSAIDs are also present.
• Pregnancy, lactation, and children: Use only under qualified clinical guidance; do not use Trikatu as a routine household supplement in these groups.
• People with strong pitta aggravation: Burning sensations, mouth ulcers, sour reflux, heat intolerance, inflamed rashes, or bleeding tendency call for a cooler, individualized plan.

Dose Boundaries

The Ayurvedic Pharmacopoeia gives separate powder doses for the individual ingredients: Maricha 500 mg–1 g, Pippali 500 mg–1.5 g, and Shunthi 1–2 g. Since Trikatu is commonly prepared from equal parts of these three drugs, a 3 g daily amount supplies about 1 g of each ingredient, reaching the upper official single-drug dose of Maricha. This makes 3 g per day a prudent upper boundary for routine adult use unless a qualified practitioner has specifically prescribed otherwise.

Safer Use Guidelines

Safe Trikatu use begins with matching the formula to the person rather than taking it as a general wellness capsule. The aim is to use the lowest effective dose, for a defined reason, with attention to heat, acidity, bleeding risk, and medication exposure.

1. Review all medicines first. Include prescription drugs, over-the-counter painkillers, anticoagulants, diabetes medicines, supplements, and herbal products.
2. Do not use Trikatu to “boost” prescription medicines. Bioavailability enhancement is not automatically beneficial and may become dangerous with narrow-therapeutic-index drugs.
3. Start low and take after food. This reduces the likelihood of burning, nausea, reflux, or gastric irritation.
4. Stop if pitta symptoms appear. Burning acidity, sour belching, mouth ulcers, heat, loose burning stools, nosebleeds, or inflamed skin are signals to stop and reassess.
5. Do not rely on timing separation alone. Piperine-related effects on enzymes and transporters are not always avoided simply by taking medicines two hours apart.
6. Use a suitable anupana. Warm water, honey, or ghee may be selected by a practitioner according to the condition, dosha pattern, and formulation goal.
7. Reassess rather than continue indefinitely. Trikatu is best used for a clear digestive or kapha-vata indication, not as an unending daily habit.

Alternatives When Piperine Interaction Risk Matters

When a person needs digestive support but cannot safely take piperine-containing formulas, the solution is not to force Trikatu into the plan. A practitioner may choose a gentler anupana, a smaller amount of Shunthi alone, non-piperine digestive measures, dietary correction, or a formulation better suited to the person’s medication profile and dosha state.

• Warm water as anupana: Often suitable for simple sluggish digestion without adding piperine exposure.
• Ghee as anupana: May be selected when the herb or condition calls for a nourishing, unctuous carrier rather than a sharp pungent enhancer.
• Honey as anupana: Traditionally used in kapha-oriented contexts, but it should not be heated and should be selected according to the person and condition.
• Non-piperine formulations: People taking interacting medicines may need formulations that avoid black pepper or long pepper altogether.

For a broader discussion of carrier substances, see The Science of Anupana.

For understanding how constitution affects tolerance to heating formulas, see Doshic Assessment at Home.

Medical Disclaimer: This article is for educational purposes only. Trikatu is a potent Ayurvedic preparation with real interaction and gastric-irritation potential. If you take prescription medicines, have reflux, ulcer disease, bleeding risk, pregnancy, lactation, diabetes medication use, or a chronic medical condition, consult a qualified Ayurvedic practitioner and your healthcare provider before using Trikatu. Do not change prescribed medication doses without medical supervision.

References

1. An Ayurvedic formulation ‘Trikatu’ and its constituents (1992), PubMed
2. Ayurvedic Pharmacopoeia of India
3. Ayurvedic Pharmacopoeia of India
4. Ayurvedic Pharmacopoeia of India
5. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 (2002), PubMed
6. Link (link.springer.com)
7. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers (1987), PubMed
8. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy (2006), PubMed
9. Effect of Piperine on the Metabolism and Pharmacokinetics of Carbamazepine in Healthy Volunteers (2017), PubMed
10. Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients (2009), PubMed
11. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers (1998), PubMed
12. Effects of piperine on gastric acid secretion in albino rats (2002), PubMed
13. Piperine inhibits gastric emptying and gastrointestinal transit in rats and mice (2001), PubMed
14. Protective action of piperine against experimental gastric ulcer (2000), PubMed
15. The Effect of Ginger (Zingiber officinale) on Platelet Aggregation: A Systematic Literature Review (2015), PubMed Central
16. The effects of ginger on fasting blood sugar, hemoglobin a1c, apolipoprotein B, apolipoprotein a-I and malondialdehyde in type 2 diabetic patients (2015), PubMed Central
17. Ayush (ayush.delhi.gov.in)
18. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers (2013), PubMed
19. Ayurvedic Pharmacopoeia of India

The cytochrome P450 enzyme system is one of the body’s major drug-processing systems, with important activity in the liver and the small intestine. A small group of CYP isoforms, especially CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4/5, handles a large share of medication metabolism. When a concentrated herbal extract, spice compound, or “bioavailability enhancer” inhibits or induces these enzymes, it may change the exposure of a co-administered medicine. In practical terms, inhibition can raise drug levels, while induction can lower them.

This does not mean that every Ayurvedic herb automatically causes a dangerous interaction. It means that dose, formulation, route, duration, the patient’s genetics, and the medication’s safety margin matter. Culinary turmeric in food is not the same risk category as a high-dose curcumin capsule combined with piperine. Likewise, a laboratory signal is not the same as a proven clinical event, but it is enough to justify caution when the patient is taking medicines with a narrow therapeutic index.

The CYP450 System: A Quick Primer

Several CYP isoforms are repeatedly relevant in herb-drug interaction screening. The table below lists common medication examples and botanicals for which published CYP or transporter signals exist. These entries should be read as practical caution points, not as proof that every product or every patient will experience the same effect.

Piperine: The Main Bioavailability Enhancer to Watch

Piperine is an alkaloid found in black pepper (Piper nigrum) and long pepper or Pippali (Piper longum). In Ayurveda, pepper-containing combinations are often used to support digestion and improve the effectiveness of formulations. In modern pharmacokinetic terms, piperine is important because it can inhibit human CYP3A4 and P-glycoprotein, two systems that normally limit the absorption and persistence of many medicines.

The best-known human example is the curcumin-piperine combination: 20 mg of piperine markedly increased the measured bioavailability of curcumin in healthy volunteers. That same “enhancement” principle is useful when intentionally designing curcumin supplements, but it also explains why piperine-containing products deserve caution when taken near prescription medicines. The risk is highest when the other medicine depends on CYP3A4 or P-gp and has a narrow safety window.

Clinical Implications

The practical concern is not ordinary seasoning in food; it is concentrated piperine, “Bioperine,” or similar absorption-enhancing extracts taken with medicines that require stable blood levels.

• Statins: Simvastatin and atorvastatin are sensitive to interaction pathways involving CYP3A4. Increased statin exposure can increase the risk of muscle toxicity, including myopathy and rhabdomyolysis.
• Warfarin: Warfarin exposure and INR can be altered by inhibitors or inducers of CYP2C9, CYP1A2, and CYP3A4. Patients on warfarin should not add concentrated herbal extracts without INR-aware medical supervision.
• Immunosuppressants: Cyclosporine and tacrolimus are CYP3A/P-gp-sensitive medicines with narrow therapeutic windows. Small changes in exposure can be clinically important.
• Sedatives: Several benzodiazepines are CYP3A substrates. Combining them with CYP3A inhibitors may increase sedation, impairment, and respiratory-risk concerns, especially with alcohol, opioids, or sleep medicines.

Curcumin and Turmeric: Food Spice Is Not the Same as a High-Dose Extract

Haridra, or turmeric (Curcuma longa), is widely used as a food spice and Ayurvedic ingredient. Whole turmeric powder contains a relatively small percentage of curcuminoids compared with standardized curcumin supplements, and curcumin itself has poor oral bioavailability unless formulated with enhancers such as piperine, fats, phospholipids, nanoparticles, or other delivery systems.

Curcuminoids can inhibit multiple human drug-metabolizing enzymes in vitro, including CYP3A and CYP2C9, and can also affect conjugation pathways such as UGT and SULT. For most people, turmeric used in normal cooking is unlikely to behave like a high-dose pharmacological extract. The interaction concern rises with concentrated curcumin capsules, high daily doses, and especially curcumin products combined with piperine.

Patients taking anticoagulants, antiplatelet medicines, transplant medicines, anti-seizure medicines, sedatives, diabetes medicines, or cancer therapies should treat high-dose curcumin supplements as clinically relevant products rather than as ordinary kitchen spices. Medication changes should be made only with guidance from a qualified healthcare provider.

Guggulu and Guggulsterones: Induction Can Lower Drug Exposure

Guggulu is the resinous exudate obtained from Commiphora species used in classical and contemporary Ayurvedic formulations. Its steroidal constituents, known as guggulsterones, can activate the pregnane X receptor, a nuclear receptor that regulates CYP3A expression. This makes guggulu different from a simple CYP inhibitor: in some contexts, the concern is faster drug metabolism and lower drug exposure.

Formulations such as Yogaraja Guggulu, Kanchanara Guggulu, Triphala Guggulu, and other guggulu-containing preparations may be used for long periods. Because the guggulsterone content and pharmacokinetic effect can vary by product, patients taking CYP3A-sensitive medicines should disclose guggulu use to both their physician and Ayurvedic practitioner.

Other Botanicals with Relevant CYP Signals

Several Ayurvedic or Ayurveda-adjacent botanicals have published CYP interaction signals, but the strength of evidence varies. These signals are most useful for identifying when extra caution is needed, especially with narrow-therapeutic-index medicines.

How to Think About Risk in Real Life

Herb-drug interaction risk becomes more important when three factors overlap: a concentrated extract, a medicine with a narrow therapeutic index, and a patient whose drug level is already being closely balanced. Warfarin, digoxin, lithium, tacrolimus, cyclosporine, antiepileptics, theophylline, antiarrhythmics, chemotherapy, sedatives, and some antiretroviral or antifungal medicines deserve special caution.

Timing doses apart may reduce direct gastrointestinal interference in some cases, but it does not reliably prevent CYP or P-gp interactions because enzyme and transporter effects can persist beyond the moment of dosing. A safer approach is medication reconciliation, cautious dosing, monitoring, and communication between the patient’s physician, pharmacist, and qualified Ayurvedic practitioner.

Practical Guidelines for Practitioners and Patients

The safest integration of Ayurveda and conventional medicine starts with full disclosure and risk ranking, not blanket rejection of either system.

For Ayurvedic Practitioners

Before starting a concentrated herbal formulation, especially one containing piperine, curcumin extract, guggulu, Bacopa, or Andrographis, review the patient’s current medicines and identify narrow-therapeutic-index drugs.

• Ask specifically about medicines and supplements. Include prescription drugs, over-the-counter medicines, vitamins, protein powders, herbal capsules, teas, and “bioavailability-enhanced” products.
• Flag narrow-safety-window medicines. Warfarin, tacrolimus, cyclosporine, digoxin, lithium, theophylline, anti-seizure medicines, chemotherapy, and sedatives should trigger extra caution.
• Avoid adding multiple new products at once. If an interaction occurs, single-step changes make it easier to identify the cause.
• Coordinate monitoring. INR, drug trough levels, liver enzymes, kidney function, blood glucose, sedation, blood pressure, or symptom control may need monitoring depending on the medicine involved.

For Patients

Patients should treat concentrated Ayurvedic extracts as active medicinal products, even when they are sold as natural supplements.

• Tell every provider what you take. Your physician should know about Ayurvedic herbs and supplements, and your Ayurvedic practitioner should know about all prescription medicines.
• Be careful with “black pepper extract” products. Piperine is intentionally added to increase absorption, and that effect is not limited to the herb advertised on the label.
• Watch for new symptoms after starting a supplement. Unusual drowsiness, dizziness, bruising, bleeding, muscle pain, dark urine, unstable blood sugar, palpitations, tremor, or loss of medication effect should be reported promptly.
• Do not stop prescribed medicines on your own. The safer step is to contact the prescribing clinician and discuss whether monitoring or dose adjustment is needed.

The Bigger Picture: Safer Integration, Not Fear

CYP450 herb-drug interactions should not create fear of Ayurveda. They should create better clinical habits. The same herb that is appropriate for one person may be risky for another because the second person is taking warfarin, tacrolimus, a sedative, chemotherapy, or a complex drug regimen. Product strength also matters: food-level spice use, traditional formulations, standardized extracts, and piperine-enhanced capsules are not equivalent.

Ayurveda has always emphasized individual assessment, context, dose, digestive capacity, compatibility, and proper administration. Modern pharmacology adds another layer: enzyme pathways, transporters, genetic variation, and drug monitoring. When both perspectives are used carefully, integration becomes safer and more rational.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Herb-drug interactions can be clinically significant and sometimes dangerous. Do not start, stop, or change any prescribed medication without consulting your physician. If you take prescription medicines, are pregnant, have liver or kidney disease, are preparing for surgery, or are managing a chronic condition, consult both your physician and a qualified Ayurvedic practitioner before adding herbal supplements, detoxes, or therapeutic protocols.

References

1. NCBI
2. Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism (2016), PubMed Central
3. Medsafe (medsafe.govt.nz)
4. FDA
5. Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein (2015), PubMed Central
6. Pib (pib.gov.in)
7. Pib (pib.gov.in)
8. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 (2002), PubMed
9. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers (1998), PubMed
10. Immunomodulatory and antitumor activity of Piper longum Linn. and piperine (2004), PubMed
11. SAGE Journals
12. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor (2008), PubMed
13. Curcumin content of turmeric and curry powders (2006), PubMed
14. Cot (cot.food.gov.uk)
15. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor (2004), PubMed
16. Ayurvedic Pharmacopoeia of India
17. Ayurvedic Pharmacopoeia of India
18. Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents (2014), PubMed
19. Effects of Andrographis paniculata extract and Andrographolide on hepatic cytochrome P450 mRNA expression and monooxygenase activities after in vivo administration to rats and in vitro in rat and human hepatocyte cultures (2009), PubMed
20. The effects of Andrographis paniculata (Burm.f.) Nees extract and diterpenoids on the CYP450 isoforms’ activities, a review of possible herb-drug interaction risks (2015), PubMed
21. Metabolism-mediated interaction potential of standardized extract of Tinospora cordifolia through rat and human liver microsomes (2016), PubMed Central
22. NIH Office of Dietary Supplements
23. FDA
24. NCBI
25. FDA
26. Controversial Interactions of Tacrolimus with Dietary Supplements, Herbs and Food (2022), PubMed Central
27. NCBI

Anupana has a broader and more precise classical meaning than “absorption enhancer.” In Charaka Samhita, Sutra Sthana 27, the discussion is primarily about a suitable drink taken with or after food, selected in relation to the meal and so that it is not harmful to dosha or dhatu. Later pharmacy also applies anupana to a substance given with or after medicine. Sahapana, emphasized in later Rasa-shastra literature, refers to a medium administered together with medicine; it is not a synonym for every kind of herbal synergy. Traditional prescribing and modern pharmacokinetics may overlap, but they are not interchangeable.

Why Anupana Matters: Form, Context and Bioavailability

Bioavailability is the proportion of an administered substance that reaches systemic circulation in a measurable form. It is not the only measure of activity: a preparation may act locally in the gut, be converted into metabolites, or contain constituents with different absorption profiles. A single percentage therefore cannot describe an entire herb.

• Curcumin: Human studies find low and variable systemic exposure because of limited aqueous solubility, metabolism and elimination. Exposure depends on dose, analytical method and formulation; “1% bioavailability” is not universal.
• Berberine and quercetin: Oral exposure varies with chemical form, food matrix, metabolism and product. Broad ranges such as “5–20%” or “0–50%” are too imprecise to guide clinical use.
• Ashwagandha: Human withanolide studies examine particular standardized extracts; they do not justify a universal 20–40% figure for all ashwagandha products.

Charaka does not describe CYP enzymes, P-glycoprotein, chylomicrons or modern tissue targeting. Sutra Sthana 27, verses 319–326, says an appropriate post-prandial drink is chosen according to the food and person, and describes nourishment, satisfaction, softening and liquefaction of food, digestion, assimilation and diffusion. These classical observations may inspire hypotheses, but should not be rewritten as direct statements of contemporary pharmacokinetics.

Major Anupana Categories: What Is Traditional and What Is Proven

The same substance can be food, vehicle, adjuvant or medicine depending on context. The table separates classical use, reasonable formulation principles and claims that still require direct testing.

Piperine: The Best-Studied Example, with Important Limits

Shoba and colleagues gave healthy volunteers 2 g of curcumin alone or with 20 mg of piperine. Levels were very low or undetectable after curcumin alone, whereas co-administration produced higher concentrations during the first hour; the area-under-the-curve calculation yielded a reported 2000% increase. This small, single-dose experiment used isolated piperine. It did not show that household black pepper reproduces the result or establish long-term efficacy.

The 1998 paper referred to inhibition of glucuronidation, but did not demonstrate CYP3A4 or P-glycoprotein inhibition in those volunteers. Earlier laboratory work showed reduced glucuronidation, and a later human-cell and microsomal study found P-glycoprotein and CYP3A4 inhibition. These are plausible mechanisms, but in-vitro results do not predict the size of an interaction in an individual patient.

Trikatu is Shunthi (dry ginger), Maricha (black pepper) and Pippali (long pepper). It occurs in many formulations, but no authoritative source supports the claim that every classical Haridra formula contains it. Combinations may address taste, digestion, dosage form and therapeutic intent; one modern piperine-curcumin experiment cannot prove the purpose of every traditional prescription.

Ghrita: A Lipid Dosage Form, Not Automatically a Nano-Carrier

Medicated ghrita is a genuine Ayurvedic pharmaceutical dosage form in which a lipid medium is processed with herbal materials according to a defined method. Modern oral-delivery science confirms the general principle that lipids can improve the apparent solubility and intestinal presentation of some poorly water-soluble molecules. Lipid digestion can also support intestinal lymphatic transport for compounds whose physicochemical properties favor that route.

That principle does not mean that any herb swallowed with ghee enters chylomicrons, avoids first-pass metabolism or becomes two to ten times more bioavailable. Lymphatic transport depends on the molecule, lipid composition, digestion, dose and formulation. Each ghrita needs direct comparative study.

Brahmi Ghrita should therefore be described as a classical multi-ingredient lipid preparation, not as a clinically proven “optimized bacoside nano-carrier.” The behavior of a finished ghrita cannot be inferred from data on one isolated constituent; preparation, identity, quality and intended indication must be assessed as a whole.

Honey as Anupana: Classical Guidance without Modern Overreach

Charaka Samhita, Sutra Sthana 27, verses 245–249, describes honey as sweet and astringent, dry, heavy and cooling, and calls it an excellent yogavahi or vehicle because it is composed of many substances. The same passage warns against heated or warm honey. This is an authentic classical instruction and should be presented as such rather than converted into an unsupported claim that honey enzymatically transforms every herb into a more absorbable drug.

Modern chemistry shows that 5-hydroxymethylfurfural (HMF), a sugar-degradation product, rises with heat and storage. Current toxicological reviews do not establish that ordinary warmed honey becomes a human poison because of HMF. The classical prohibition and the HMF observation are not equivalent proof, and one should not be presented as scientific validation of the other.

Honey’s viscosity and sweetness can make powdered medicines easier to administer, but evidence for systemic “permeability enhancement,” targeted delivery to skin or nerves, or prolonged contact with the lower respiratory tract is lacking. Swallowed honey does not coat the bronchi. The dose, medicine, patient and classical restriction on heating remain relevant.

Sahapana and Combination Formulation

Later Ayurvedic pharmaceutical writing uses sahapana for a substance mixed with and administered together with a medicine. A review of the term reports that it is not found in earlier Ayurvedic texts before Rasa Tarangini. It is therefore historically misleading to make Sahapana a major doctrine of Charaka or to define it broadly as any pair of herbs that “mutually potentiates” each other.

Combination formulation remains important. Co-administered ingredients can change taste, dispersion, dissolution, gastric emptying, metabolism, transport and toxicity. Effects are not always beneficial; an ingredient may reduce exposure, intensify an adverse effect or interact with a drug. “Synergy” should be demonstrated for a specified formula and outcome.

Claims that Triphala functions as a controlled-release tannin matrix for unrelated medicines, or that Vidanga is a general intestinal permeation enhancer, lack direct formulation-specific clinical support. Likewise, laboratory findings on Piper longum or its constituents cannot be used to promise predictable CYP inhibition or improved absorption in patients.

Emerging Research: Formulation Parallels, Not Equivalence

Traditional dosage forms can be studied with modern tools, but resemblance is not equivalence. Lipid formulations may form emulsified or colloidal structures during processing and digestion, fermented preparations contain complex products, and milk proteins can be engineered into carriers. None of this makes every ghrita, asava, arishta or milk anupana a standardized nanomedicine.

Some bhasma studies report micro- or nanoscale particles and altered chemical forms compared with starting material. Size varies with material and manufacturing, and nanoscale particles alone prove neither bioavailability nor safety. Characterization, reproducible manufacture, quality control and toxicology remain essential; “Swarna Bhasma is always 56–78 nm” is not defensible across products.

Bhasma and other mineral-containing products should not be recommended for casual self-treatment on a nanoparticle analogy. Identity, processing, contamination testing, dose and clinical supervision are essential. A “nano” label does not rescue a poorly characterized product, and historical use does not replace safety assessment.

Practical Anupana Guide: Use the Prescribed Context

The practical lesson is not to treat anupana as a universal absorption hack. The medicine, dosage form, food, digestive state, dosha assessment, disease, age and strength of the patient may alter the choice. Changing the vehicle can change the prescription.

• Classical powders, decoctions, ghrita and avaleha: Follow the exact formula’s instructions or a qualified practitioner. Do not add milk, ghee, honey or pepper merely because they are used elsewhere.
• Turmeric used as food: It may be eaten in a normal meal, including one containing fat. This is not equivalent to 2 g purified curcumin with 20 mg isolated piperine, so no “2000%” promise applies to kitchen turmeric.
• Curcumin supplements: Formulations differ substantially. Follow the product directions and seek professional advice rather than adding concentrated piperine to a product that may already contain an enhancer.
• Milk or ghee vehicles: These are not suitable for everyone, including people with milk allergy, lactose intolerance or individualized dietary-fat restrictions.
• Honey vehicles: When following classical use, do not cook or heat the honey with the medicine. People for whom sugar intake requires restriction should obtain individualized advice.
• Piperine supplements: Review all medicines with a pharmacist or physician. Laboratory and human pharmacokinetic studies show that concentrated piperine can alter the handling of some medicines.

For related evidence reviews, see our post on Kutki (Picrorhiza kurroa) research and our systematic review of Ayurvedic hepatoprotective herbs. Evidence for a botanical or finished formulation must be judged on its own methods and outcomes; anupana theory cannot substitute for direct clinical data.

The most responsible change is methodological: do not convert every classical vehicle into a bioavailability claim. Preserve the textual context, identify the product and dose, distinguish culinary pepper from isolated piperine, and ask whether the mechanism was demonstrated in humans for that formulation.

Disclaimer: This article is educational and is not a prescription. Concentrated piperine and some herbal or mineral preparations may alter drug exposure or cause adverse effects. Consult a qualified Ayurvedic practitioner and a physician or pharmacist before changing a prescribed anupana, combining supplements with medicines, or using bhasma or other mineral-containing products.

References

1. Charaka Samhita — Annapanavidhi Adhyaya
2. Jaims (jaims.in)
3. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 (2002), PubMed
4. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers (1998), PubMed
5. Piperine-mediated inhibition of glucuronidation activity in isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogeneous UDP-glucuronic acid content (1986), PubMed
6. Study on influence of piperine treatment on the pharmacokinetics of diclofenac in healthy volunteers (2017), PubMed
7. An Ayurvedic formulation ‘Trikatu’ and its constituents (1992), PubMed
8. Bioavailability of curcumin: problems and promises (2007), PubMed
9. Pharmacokinetics and bioequivalence of Withania somnifera (Ashwagandha) extracts – A double blind, crossover study in healthy adults (2023), PubMed
10. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs (2007), PubMed
11. Ayurvedic lipid based rasayans – A perspective on the preparation and pharmacological significance of lipids on the bioavailability of phytoconstituents (2022), PubMed Central
12. Lipid-based formulations for oral administration of poorly water-soluble drugs (2013), PubMed
13. Beta-casein-based nanovehicles for oral delivery of chemotherapeutic drugs: drug-protein interactions and mitoxantrone loading capacity (2010), PubMed
14. The role of 5-hydroxymethylfurfural in food and recent advances in analytical methods (2022), PubMed
15. Dietary glycation compounds – implications for human health (2024), PubMed
16. Bhasma : The ancient Indian nanomedicine (2014), PubMed Central
17. Preparation and Characterization of Suvarna Bhasma Parada Marit (2017), PubMed
18. Blood compatibility studies of Swarna bhasma (gold bhasma), an Ayurvedic drug (2011), PubMed
19. NCCIH

The Shoba et al. Pharmacokinetic Study

The paper, “Influence of Piperine on the Pharmacokinetics of Curcumin in Animals and Human Volunteers,” was published in Planta Medica in 1998. Ten healthy male volunteers were enrolled, with pharmacokinetic analysis reported for eight. Participants received 2 g of curcumin alone and 2 g of curcumin with 20 mg of piperine. Blood sampling continued for six hours.

The same paper included a rat experiment using 2 g/kg of curcumin with or without 20 mg/kg of piperine. Piperine increased the reported bioavailability of curcumin by 154% in rats. The rat and human estimates are not interchangeable because species, dose scale, sampling, and baseline detectability differed.

Why Standard Curcumin Produces Low Circulating Levels

Curcumin is one of the principal curcuminoids of turmeric, but an oral dose does not move unchanged into the bloodstream in a simple one-to-one manner. Its limited water solubility constrains dissolution in gastrointestinal fluid, absorption is incomplete, and absorbed curcumin is rapidly transformed through conjugation reactions such as glucuronidation and sulfation. Metabolites and unabsorbed material are then eliminated, leaving low concentrations of free curcumin in plasma after many conventional preparations.

A Phase I dose-escalation study published by Lao and colleagues in 2006 gave standardized curcuminoids to 24 healthy volunteers in single doses ranging from 500 mg to 12 g. Curcumin was not detected in serum after doses from 500 mg through 8 g; low serum concentrations were found in two participants receiving 10 g or 12 g. These findings do not mean that every turmeric food, extract, or curcumin product behaves identically.

How Piperine May Alter Curcumin Exposure

The Shoba trial demonstrated a pharmacokinetic change but did not directly identify its molecular cause in the volunteers. Experimental work on piperine supports two relevant pathways: inhibition of some metabolic reactions and modification of intestinal membrane characteristics. Their magnitude depends on preparation, dose, timing, and co-administered substances.

Effects on Glucuronidation and Drug Metabolism

Animal and laboratory studies by Atal and colleagues and by Singh and colleagues found that piperine can inhibit hepatic drug-metabolizing activity and reduce glucuronidation in experimental systems. This can help explain slower presystemic conversion of some compounds. Piperine is better understood as a broad metabolic modulator than as a curcumin-specific enhancer or a clinically established inhibitor of particular human UGT isoenzymes at every supplement dose.

Effects on the Intestinal Brush Border

Khajuria and colleagues examined piperine in experimental intestinal models and reported changes in brush-border membrane fluidity, ultrastructure, and enzyme kinetics. Such findings can help explain altered passage or handling of co-administered compounds, but they were not demonstrations of a controlled, temporary increase in human intestinal permeability. The human result therefore does not prove a single settled mechanism.

Haridra and Maricha in the Ayurvedic Pharmacopoeia

Ayurveda distinguishes the whole medicinal substances from isolated curcumin and piperine. The Ayurvedic Pharmacopoeia of India identifies Haridra as the dried and cured rhizome of Curcuma longa and Maricha as the fully mature dried fruit of Piper nigrum. Their pharmacopoeial attributes describe traditional dravyaguna properties and should not be treated as synonyms for modern plasma pharmacokinetics.

The Maricha monograph lists Trikatu Curna among its important formulations. Trikatu is composed of Maricha, Pippali (Piper longum fruit), and Shunthi (dried Zingiber officinale rhizome), conventionally in equal parts. This establishes an authentic Ayurvedic context for pepper-containing formulation practice. It does not establish that the Shoba protocol was a classical formula: that experiment used isolated curcumin and piperine at fixed doses, not Haridra and Trikatu as described in Ayurvedic pharmacy.

Piperine-Free Curcumin Formulations

Several proprietary formulations attempt to increase curcuminoid exposure without piperine. Their published fold increases arise from separate studies with different products, doses, comparators, assays, metabolites, and sampling windows. The numbers therefore describe each experiment and cannot serve as a direct ranking of clinical effectiveness.

BCM-95

BCM-95 combines curcuminoids with a turmeric essential-oil fraction. In an 11-subject crossover pilot study, Antony and colleagues reported approximately 6.93-fold greater relative bioavailability than standard curcumin and approximately 6.37-fold greater exposure than the study’s curcumin-lecithin-piperine comparator after a 2 g dose. The formulation contains no added piperine, but the experiment did not prove superior clinical outcomes or absence of interactions.

Meriva

Meriva is a lecithin-based curcuminoid formulation. A 2011 crossover study by Cuomo and colleagues reported that total curcuminoid absorption was about 29-fold higher than with an unformulated curcuminoid mixture. The investigators detected phase-II curcuminoid metabolites rather than free curcumin in plasma, an important detail when comparing its figure with studies that quantified different analytes.

Theracurmin

Theracurmin is a colloidal submicron dispersion formulated with components including gum ghatti. In a seven-volunteer crossover experiment using 30 mg of curcumin, Sasaki and colleagues reported a 27.3-fold higher six-hour plasma AUC than curcumin powder. The result applies to that formulation and comparator; it is not a validated conversion factor for all nanoparticle products.

What the Fold Increases Mean

The principal pharmacokinetic findings can be summarized without treating unlike studies as a head-to-head contest.

Drug-Interaction and Safety Considerations

Piperine’s metabolic effects are not limited to curcumin. Small human pharmacokinetic studies have reported altered exposure to medicines including phenytoin, propranolol, and theophylline when piperine was co-administered. Experimental evidence also characterizes piperine as a nonspecific inhibitor of drug metabolism. These observations do not predict the exact effect in every patient, but concentrated piperine cannot be assumed equivalent to ordinary culinary use.

Greater absorption is not automatically safer. The U.S. National Center for Complementary and Integrative Health notes that liver injury has been reported with some bioavailability-enhanced curcumin products and advises people taking medicines to discuss herbal products with a healthcare provider. Product composition also matters: whole turmeric, standardized curcuminoids, phospholipid complexes, colloidal dispersions, and curcumin-piperine combinations should not be assumed to have the same exposure or risk profile.

Practical Interpretation

The most defensible lesson from the available pharmacokinetic literature is that formulation can substantially alter circulating curcuminoid levels. That observation should guide careful product identification and medication review rather than produce a single universal rule for everyone.

1. The 2,000% figure is study-specific. It represents approximately twentyfold relative exposure in a small, single-dose experiment, not a guaranteed response to sprinkling black pepper on turmeric.
2. Bioavailability and clinical efficacy are different outcomes. A larger plasma AUC does not by itself establish better symptom relief, tissue delivery, long-term safety, or an appropriate therapeutic dose.
3. Ayurvedic drugs and isolated constituents are not interchangeable. Haridra and Maricha have defined botanical identities and traditional pharmacopoeial properties; curcumin and piperine are selected constituents used in modern experimental formulations.
4. Labels require close reading. The amount of curcuminoids, piperine, excipients, and the named delivery system determine which evidence, if any, is relevant to a product.

Concentrated curcumin or piperine supplements should be selected with guidance from a qualified Ayurvedic practitioner and a healthcare professional or pharmacist, particularly when prescription medicines are used, during pregnancy or breastfeeding, or when there is existing liver disease. Supplements should not replace prescribed treatment, and symptoms suggestive of liver injury require prompt medical assessment.

Related background is available in our articles on turmeric in Ayurvedic practice, the composition and use of Trikatu, and seasonal considerations for turmeric products.

References

1. Drmajeed (drmajeed.com)
2. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers (1998), PubMed
3. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice (2014), PubMed Central
4. Dose escalation of a curcuminoid formulation (2006), PubMed Central
5. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism (1985), PubMed
6. Piperine-mediated inhibition of glucuronidation activity in isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogeneous UDP-glucuronic acid content (1986), PubMed
7. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics (2002), PubMed
8. Ayurvedic Pharmacopoeia of India
9. Ayurvedic Pharmacopoeia of India
10. An Ayurvedic formulation ‘Trikatu’ and its constituents (1992), PubMed
11. A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), A Novel Bioenhanced Preparation of Curcumin (2008), PubMed Central
12. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation (2011), PubMed
13. Innovative preparation of curcumin for improved oral bioavailability (2011), PubMed
14. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers (1991), PubMed
15. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy (2006), PubMed
16. NCCIH

The widely quoted 2,000% figure comes from a 1998 pharmacokinetic experiment by Shoba and colleagues. Healthy volunteers received a single oral dose of 2 g curcumin, either alone or immediately followed by 20 mg piperine. Curcumin concentrations after curcumin alone were undetectable or very low, whereas co-administration with piperine produced higher serum concentrations during the first hour. The calculated relative increase in bioavailability, based on the area under the serum concentration-time curve, was 2,000%.

This result does not mean that piperine increased every curcumin concentration twentyfold, that the combination remained in circulation twenty times longer, or that it produced twenty times the clinical benefit. The percentage was derived from a small, single-dose comparison in which the curcumin-only values were close to the analytical detection limit. It remains an important pharmacokinetic finding, but it is not a universal efficacy statistic.

Curcumin has limited systemic availability after ordinary oral administration because of poor absorption, extensive intestinal and hepatic metabolism, and rapid elimination. Piperine can modify some of the enzymes and transporters involved in these processes. The magnitude of the effect depends on the compound, dose, formulation, duration of administration, analytical method, and characteristics of the person taking it.

Ayurveda provides a separate framework for understanding Haridra (Curcuma longa), Maricha (Piper nigrum), Pippali (Piper longum), and Shunthi (Zingiber officinale). These are complete medicinal substances with distinct rasa, guna, virya, vipaka, and karma. Their traditional use should not be reduced to the action of one isolated alkaloid.

What the 2,000% Figure Actually Measures

Bioavailability describes the fraction and rate at which an administered compound reaches systemic circulation. In pharmacokinetic studies it is commonly assessed through measurements such as maximum concentration, time to maximum concentration, half-life, clearance, and area under the concentration-time curve. A large relative increase can occur when the comparison value is extremely small, as happened when serum curcumin after the curcumin-only dose was near or below the assay’s limit of detection.

In the rat portion of the Shoba experiment, curcumin was administered at 2 g/kg and piperine at 20 mg/kg. Piperine increased calculated curcumin bioavailability by 154%. In the human portion, the doses were 2 g total curcumin and 20 mg piperine, and the calculated increase was 2,000%. The animal and human percentages are therefore not interchangeable, and neither percentage establishes an appropriate daily treatment dose.

Systemic exposure is also different from therapeutic effectiveness. A formulation may produce higher blood concentrations without proving that it improves a particular disease, symptom, or long-term health outcome. Clinical usefulness must be evaluated separately for each preparation and indication.

How Piperine Can Alter Oral Pharmacokinetics

Piperine interacts with several components of intestinal and hepatic drug disposition. Much of the detailed mechanistic work has been performed in cultured intestinal cells, human liver microsomes, recombinant enzymes, or animal models. Human experiments demonstrate that clinically relevant pharmacokinetic interactions can occur, but they do not establish one uniform mechanism or effect size for every substance.

CYP3A Enzyme Inhibition

CYP3A enzymes participate in the intestinal and hepatic metabolism of many medicines and natural compounds. In human liver microsomes, piperine inhibited CYP3A4-mediated metabolism of verapamil. A separate enzyme study characterized piperine as a relatively selective, noncompetitive inhibitor of CYP3A, with less inhibition of the other enzymes evaluated. These were laboratory experiments rather than trials in volunteers.

A small human trial used midazolam as a marker of CYP3A activity. Twenty volunteers received 15 mg piperine or placebo for three days and then 10 mg midazolam on the fourth day. Piperine pretreatment increased midazolam half-life, reduced its calculated clearance, and prolonged sedation. This illustrates why concentrated piperine may alter the action of medicines that depend on CYP3A-mediated clearance.

P-Glycoprotein Modulation

P-glycoprotein is an efflux transporter expressed in tissues including the intestinal epithelium. It can move certain absorbed compounds back toward the intestinal lumen and thereby restrict systemic exposure. Bhardwaj and colleagues examined piperine in Caco-2 intestinal cell monolayers and human liver microsomes. Piperine inhibited P-glycoprotein-mediated transport of digoxin and cyclosporine in the cell model and inhibited CYP3A4-mediated verapamil metabolism in microsomes.

The Bhardwaj experiment was not a human supplementation trial and did not administer 20 mg piperine to volunteers. Its importance lies in identifying plausible transporter and enzyme interactions under controlled laboratory conditions. Whether the same degree of inhibition occurs in a person depends on the intestinal concentration achieved, the preparation used, exposure time, and the accompanying medicine.

Glucuronidation and Conjugation

Curcumin is extensively converted to conjugated metabolites, including glucuronides and sulfates. This metabolism contributes to the low concentration of unconjugated curcumin in circulation. Piperine has affected intestinal glucuronidation in preclinical experiments, but the relevant enzyme effects are more complex than a general suppression of all UDP-glucuronosyltransferases.

In the enzyme panel reported by Volak and colleagues, piperine behaved principally as a CYP3A inhibitor. The curcuminoid extract, rather than piperine alone, produced the broader inhibition of UGT, SULT, CYP2C9, CYP2C19, and other activities. In a mouse experiment involving epigallocatechin gallate, piperine reduced intestinal glucuronidation and increased plasma exposure, demonstrating that conjugation can be altered in a compound- and model-specific manner.

Verified Pharmacokinetic Findings

Piperine has been evaluated with several structurally different substances. The results vary substantially, and animal findings cannot be converted directly into human dosing advice. The following table separates human observations from preclinical data and states what was actually measured.

These findings establish that piperine can modify exposure to selected compounds. They do not establish a predictable percentage for every herb, vitamin, medicine, or phytochemical. Duration also matters: the significant CoQ10 finding appeared after 21 days, whereas the curcumin experiment examined a single dose.

Haridra in the Ayurvedic Pharmacopoeia

The Ayurvedic Pharmacopoeia of India identifies Haridra as the dried rhizome of Curcuma longa. Its monograph lists essential oil and curcumin among its constituents. Haridra is described as katu and tikta in rasa, ruksha in guna, ushna in virya, and katu in vipaka. Listed actions include krimighna, kushthaghna, varnya, vishaghna, kaphapittanut, and pramehanashaka.

This profile belongs to the whole Haridra drug and cannot be assigned automatically to purified curcumin. Turmeric powder, standardized turmeric extract, isolated curcumin, curcuminoid mixtures, phospholipid preparations, nanoparticles, and curcumin-piperine products may differ in composition, absorption, metabolism, safety, and clinical performance.

Trikatu Is a Classical Formula, Not a Piperine Capsule

The Ayurvedic Formulary of India lists Trikatu Curna as formulation 7:14 and attributes its formula to the Bhaishajya Ratnavali, Paribhasha Prakarana, verse 16. It contains one part Pippali fruit, one part Maricha fruit, and one part Shunthi rhizome. The Formulary gives honey or warm water as the anupana and records a general adult dose of 1–3 g, while its general notices state that formulary doses are guidance and require professional judgment.

The Formulary lists traditional indications including arocaka, agnimandya, amadosha, disorders of the throat, cough, and dyspnoea. These indications place Trikatu primarily within an Ayurvedic assessment of appetite, digestion, metabolism, Kapha, Vata, and respiratory function. The monograph does not define Trikatu as a standardized milligram dose of piperine or promise a fixed increase in the absorption of every accompanying medicine.

Maricha

The Pharmacopoeia identifies Maricha as the mature dried fruit of Piper nigrum and lists piperine, chavicine, piperidine, piperettine, and essential oil among its constituents. Its rasa is katu and tikta; its gunas are laghu, ruksha, and tikshna; its virya is ushna; and its vipaka is katu. Its actions include dipana, rucya, Kapha-reducing and Vata-reducing actions, as well as pittakara. Maricha is therefore not an indiscriminate, constitution-neutral addition to every prescription.

Pippali

Pippali consists of the dried immature fruits of Piper longum. The Pharmacopoeia describes its rasa as madhura, katu, and tikta; its gunas as laghu and snigdha; its virya as anushna; and its vipaka as madhura. Listed actions include dipana, rucya, kaphahara, vatahara, rasayana, and recana. These attributes distinguish Pippali from Maricha even though both belong to the genus Piper and can contain piperine.

Shunthi

Shunthi is the dried rhizome of Zingiber officinale. Its Pharmacopoeial constituents include essential oil, gingerol, shogaol, resinous matter, and starch. It is described as katu in rasa, laghu and snigdha in guna, ushna in virya, and madhura in vipaka. Its actions include anulomana, dipana, pacana, and reduction of Vata and Kapha.

Trikatu consequently combines three drugs whose Ayurvedic profiles overlap but are not identical. Its formulation logic includes the qualities of the complete fruits and rhizome, their proportions, processing, dose, indication, patient, and anupana. Isolated piperine represents only one constituent of this wider pharmaceutical context.

Ayurvedic Formulation and Modern Bioavailability Are Related but Distinct Ideas

Ayurvedic pharmacy considers the identity and part of each drug, method of preparation, proportion, dose, route, anupana, digestive capacity, dosha pattern, and therapeutic purpose. Modern pharmacokinetics evaluates absorption, distribution, metabolism, transport, and elimination through measurable concentrations and metabolites. Both frameworks pay close attention to how administration changes a medicine’s effect, but their technical categories are not interchangeable.

Trikatu may accompany other formulations in Ayurvedic practice because of its dipana, pacana, rucya, and Kapha-Vata-related actions. Describing every such use as CYP3A4 inhibition or P-glycoprotein blockade would omit most of the traditional rationale and could create unsafe expectations. Conversely, isolated piperine may produce pharmacokinetic interactions that are not predicted solely from the traditional description of a small amount of whole Maricha within a compound formula.

The same distinction applies to anupana. Honey and warm water are specified for Trikatu in the Formulary, but this does not mean that every carrier has been proven to increase systemic absorption or cross the blood-brain barrier. Anupana remains part of individualized Ayurvedic prescribing rather than a universal molecular-delivery claim.

Implications for Curcumin Products

A curcumin product without piperine is not automatically ineffective. Some preparations are intended for local gastrointestinal exposure, while others use phospholipids, micelles, colloidal dispersions, oils, nanoparticles, or other technologies to alter absorption. Comparisons must use data for the actual formulation rather than treating all turmeric and curcumin products as equivalent.

Piperine also does not guarantee a clinically useful outcome. The National Center for Complementary and Integrative Health states that piperine is one method used to improve curcumin bioavailability, while the available clinical evidence remains insufficient for definitive conclusions about turmeric or curcumin for health purposes generally. Higher systemic exposure can increase both desired and undesired effects.

The Shoba regimen should not be converted into a general instruction to combine black pepper with ashwagandha, Triphala, vitamins, or every polyphenol-rich supplement. Each combination requires its own pharmacokinetic, clinical, and safety evaluation. The curcumin result provides a specific example, not a universal rule for herbal absorption.

Drug Interactions Require Particular Caution

Piperine has altered the pharmacokinetics of propranolol, theophylline, midazolam, and phenytoin in human investigations. These findings are especially relevant when a medicine has a narrow therapeutic range, causes dose-related sedation, or depends on intestinal transport and hepatic metabolism for predictable blood concentrations.

Possible interaction risk is not limited to one named list of drugs. Medicines substantially handled by CYP3A, P-glycoprotein, or related pathways may require caution, but the clinical effect cannot be predicted from pathway membership alone. Dose, formulation, treatment duration, genetics, liver function, kidney function, age, and additional medicines can all influence the outcome.

Ordinary culinary use of black pepper should not be treated as pharmacologically identical to a standardized concentrated piperine extract. Pepper varieties and powders differ in piperine content, storage, particle size, and serving amount. A kitchen teaspoon or “pinch” cannot be converted reliably into a precise supplemental piperine dose without chemical analysis.

More Bioavailability Can Also Mean More Risk

Increasing exposure may intensify adverse effects as well as desired actions. Piperine-containing products can cause gastrointestinal irritation in susceptible individuals and may alter medicine concentrations. The ushna, tikshna, and pittakara features recorded for Maricha also support caution in patients whose Ayurvedic assessment includes aggravated Pitta, burning, or marked irritation.

Turmeric and curcumin products can cause nausea, reflux, abdominal discomfort, diarrhoea, or constipation. Liver injury has been reported with some enhanced-bioavailability curcumin products. Fatigue, loss of appetite, nausea, dark urine, or jaundice requires prompt discontinuation and medical assessment. Turmeric supplements may also be unsafe during pregnancy, and safety above ordinary food quantities during breastfeeding remains uncertain.

People taking antiepileptic medicines, sedatives, immunosuppressants, anticoagulants, cardiovascular medicines, or any medicine requiring blood-level monitoring should not add concentrated piperine independently. A prescribing clinician or pharmacist should review the complete product label, piperine amount, curcuminoid amount, dosing schedule, and other medicines.

Dose Must Follow the Product, Purpose, and Patient

The piperine doses used in the cited human pharmacokinetic experiments ranged from 5 mg with CoQ10 to 15–20 mg with midazolam, curcumin, propranolol, or theophylline. These are study regimens rather than a general recommended range. A dose that altered one compound cannot be assumed to produce the same effect with another.

The Ayurvedic Formulary’s 1–3 g entry applies to the complete equal-part Trikatu powder and is not equivalent to 1–3 g of black pepper or to a specified amount of isolated piperine. Individual Ayurvedic prescribing may modify dose, timing, anupana, duration, and formulation according to age, strength, agni, dosha, season, condition, and concurrent treatment.

Self-measuring concentrated piperine by converting milligrams into fractions of a teaspoon is unreliable. Standardized extracts and ground pepper are materially different products, and greater exposure is not inherently better.

Practical Conclusions

The 2,000% figure is authentic, but it refers to a calculated relative AUC increase after a single 2 g curcumin dose combined with 20 mg piperine. It does not represent a universal twentyfold improvement in efficacy.

Piperine can inhibit CYP3A and P-glycoprotein under experimental conditions and has altered the disposition of several medicines in small human studies. Its influence on glucuronidation is dependent on the compound and experimental system rather than a uniform blockade of all conjugation pathways.

Trikatu is an official Ayurvedic formulation of equal parts Pippali, Maricha, and Shunthi. Its traditional description, indications, anupana, and Ayurvedic pharmacological attributes belong to the whole formulation. Trikatu should not be presented as merely an ancient name for isolated piperine.

Bioavailability enhancement is clinically relevant precisely because it can change both effectiveness and toxicity. Product-specific evidence, medicine-interaction screening, and individualized assessment are more appropriate than routinely adding concentrated piperine to every herbal preparation.

Safety Note: Concentrated piperine and enhanced-bioavailability curcumin products may alter prescription-drug exposure and can cause adverse effects. Anyone taking medication, managing liver disease, pregnant or breastfeeding, or considering therapeutic use of Trikatu, curcumin, or piperine should consult a qualified Ayurvedic practitioner and an appropriate healthcare provider. This article is educational and is not a substitute for diagnosis or treatment.

References

1. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers (1998), PubMed
2. Cot (cot.food.gov.uk)
3. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 (2002), PubMed
4. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor (2008), PubMed
5. Link (link.springer.com)
6. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers (1991), PubMed
7. Piperine derived from black pepper increases the plasma levels of coenzyme Q10 following oral supplementation (2000), PubMed
8. Enhancing the bioavailability of resveratrol by combining it with piperine (2011), PubMed
9. Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice (2004), PubMed
10. Ayurvedic Pharmacopoeia of India
11. Ayurvedic Pharmacopoeia of India
12. Ayurvedic Pharmacopoeia of India
13. Dravyaguna notes
14. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy (2006), PubMed
15. NCCIH

The practical answer is not simply “take more turmeric.” In Ayurvedic practice, turmeric is commonly used as part of a prepared food, milk, ghee, oil, or spice combination rather than as an isolated dry powder swallowed with water. Modern pharmacokinetics helps explain why black pepper, long pepper, ginger, ghee, oil, and milk can change how turmeric behaves in the body.

Here is how to make turmeric work more intelligently while staying close to authentic Ayurvedic use.

The Absorption Problem Nobody Talks About

Curcumin is fat-soluble and poorly soluble in water. When a standard curcumin extract is taken orally, only a small fraction reaches the bloodstream unchanged, and much of what is absorbed is converted into metabolites such as glucuronides and sulfates. This is why two capsules with the same “curcumin” amount on the label can perform very differently depending on the delivery system.

In one 2025 open-label human comparison, standard curcumin produced a reported Cmax of 10.94 ng/mL, while BioTurm™ reached 647.97 ng/mL and a Curcuma longa extract containing 10% piperine reached 663.60 ng/mL. These numbers should be read as product-specific pharmacokinetic findings rather than universal values for every turmeric supplement, but they illustrate the basic point: formulation matters.

The Plot Twist: Local Gut Action Matters Too

Low blood levels do not mean turmeric is useless. Oral curcumin can remain concentrated in the gastrointestinal tract, where it may interact with the intestinal lining, local immune activity, oxidative stress pathways, and the gut microbiota. This helps explain why whole turmeric in food can still be meaningful even when it does not create high systemic curcumin levels.

For general digestive and dietary use, turmeric in cooking may be enough. For systemic goals such as joint comfort or inflammatory support, a well-formulated curcumin product or a traditional preparation that includes fat and pungent spices is usually more logical than plain capsules taken with water.

The 2000% Piperine Finding

In the well-known 1998 human pharmacokinetic work by Shoba and colleagues, 20 mg of piperine taken with 2 g of curcumin increased curcumin bioavailability by 2000% in human volunteers. Piperine, the major alkaloid in black pepper, can slow the metabolic processing of curcumin and increase its measurable presence in blood.

This is powerful, but it is not a free pass to add high-dose black pepper extract to everything. Piperine can also affect drug transporters and drug-metabolising enzymes, including P-glycoprotein and CYP3A4. That is useful for curcumin absorption, but it is also why curcumin-piperine supplements need caution when prescription medicines are involved.

Ayurvedic View of Haridra

In the Ayurvedic Pharmacopoeia of India, Haridra is the dried and cured rhizome of Curcuma longa. Its listed rasa are katu and tikta, its guna is ruksha, its virya is ushna, and its vipaka is katu. Its karma include krimighna, kushaghna, varnya, vishaghna, kaphapittanut, and pramehanashaka, and the adult powder dose is listed as 1–3 g.

This classical profile is important because Ayurveda does not view turmeric as “curcumin only.” Haridra is a hot, pungent-bitter, drying rhizome traditionally used with attention to constitution, digestion, season, preparation, and anupana. A person with sluggish Kapha-type digestion may tolerate it differently from someone with hyperacidity, burning sensations, or aggravated Pitta.

Trikatu: The Digestive Formula Behind the Bioenhancer Idea

Trikatu is a classical Ayurvedic powder made from three pungent ingredients in equal parts: Maricha, Pippali, and Shunthi. In modern botanical terms, these are black pepper fruit, long pepper fruit, and dried ginger rhizome.

1. Maricha — black pepper, Piper nigrum
2. Pippali — long pepper, Piper longum
3. Shunthi — dried ginger, Zingiber officinale

Ayurveda uses Trikatu as a deepana-pachana formula, meaning it supports appetite, digestive fire, and the proper processing of food. In the context of turmeric, a small pinch of Trikatu provides piperine-containing peppers along with ginger’s warming digestive quality. It is not suitable for everyone in large amounts, especially people prone to acidity, heat, gastritis, ulcers, bleeding disorders, or strong Pitta aggravation.

Modern Bioavailability Solutions: A Comparison

The supplement industry now uses several strategies to solve the same basic problem: curcumin is difficult to absorb on its own. Some methods use piperine, some use lipids or phospholipids, and some use nanoparticle or proprietary delivery systems.

A large scoping review of curcumin clinical trials found that 45% of trials used enhanced-bioavailability products, and among musculoskeletal trials the figure was about 61.2%. This does not mean every person needs a high-tech formula, but it does show that formulation is central when curcumin is used for targeted purposes.

How to Make Golden Milk for Better Absorption

Many online golden milk recipes are pleasant turmeric lattes. A more purposeful turmeric milk should include three things: turmeric, a fat-containing base, and a small amount of black pepper or Trikatu. This keeps the preparation closer to Ayurvedic logic while also addressing curcumin’s fat-soluble nature.

Turmeric Milk

This is a simple household preparation for people who tolerate milk and warming spices well. Use smaller amounts at first if you are sensitive to heat, acidity, or pungent spices.

• 1 cup whole milk or full-fat coconut milk
• 1/2 to 1 teaspoon turmeric powder
• 1/8 teaspoon black pepper powder, or a small pinch of Trikatu
• 1/2 teaspoon ghee or coconut oil
• A small piece of jaggery, or honey added only after the drink cools to warm
• A pinch of cinnamon or cardamom, optional

Method: Warm the milk gently on low heat. Add turmeric, black pepper or Trikatu, and ghee or coconut oil. Stir for 2–3 minutes until the drink turns deep golden. Remove from heat and allow it to cool until warm. If using honey, add it only after cooling, because classical Ayurvedic guidance advises against heating honey.

Turmeric Paste

This paste is a convenient weekly concentrate for people who prefer not to measure spices every time. It should be kept refrigerated in a clean glass jar and used in small amounts.

• 1/4 cup turmeric powder
• 1/2 cup water
• 1 to 2 teaspoons Trikatu powder, or black pepper powder to taste
• 2 tablespoons coconut oil or ghee

Method: Cook the turmeric and water on low heat, stirring until a paste forms. Remove from heat and mix in the fat and pepper or Trikatu. Use about 1/2 to 1 teaspoon of paste in warm milk, adjusting the amount according to tolerance.

Common Mistakes to Avoid

Taking turmeric with plain water: Curcumin is fat-soluble, so plain water is a poor vehicle. Food, milk, ghee, or oil makes more sense than swallowing dry turmeric or curcumin with water alone.

Using too much pepper: A pinch of black pepper in food is very different from concentrated piperine extract. Piperine may improve curcumin absorption, but it can also alter drug metabolism and transport.

Megadosing curcumin: More is not automatically better. Curcumin products commonly cause gastrointestinal symptoms such as nausea, reflux, stomach upset, diarrhoea, constipation, or abdominal discomfort in some people, especially at higher doses.

Ignoring the whole herb: Whole turmeric contains more than isolated curcumin. The Ayurvedic Pharmacopoeia of India lists essential oil and curcumin as constituents of Haridra, and the classical use of turmeric depends on the whole rhizome, its qualities, and its preparation.

Forgetting drug interactions: Curcumin and turmeric supplements require caution with anticoagulant or antiplatelet medicines, surgery, bleeding disorders, gallbladder problems, and medicines affected by drug-metabolising enzymes. Piperine-containing products deserve extra caution.

What Should You Actually Do?

For culinary use, keep using turmeric in dals, sabzis, soups, curries, and rice dishes. Add it during cooking with ghee or oil, and include a little black pepper when appropriate for your constitution and digestion.

For a more traditional household routine, turmeric milk with ghee and a small amount of black pepper or Trikatu is more sensible than plain turmeric in hot water. Start small, observe digestion, and avoid forcing it if it causes burning, reflux, nausea, loose stools, or heat symptoms.

For targeted supplementation, choose a product that clearly states its curcuminoid content and delivery method. Curcumin-piperine products are common and affordable, while liposomal, phospholipid, and nanoformulated products may be suitable for people avoiding piperine. For joint comfort, many clinical trials run for about 8 weeks or longer, so judging a product after only a few days is usually premature.

Frequently Asked Questions

These answers apply to general adult use and do not replace individual advice from an Ayurvedic practitioner, doctor, pharmacist, or other qualified healthcare professional.

Why does plain turmeric have such low absorption?

Curcumin is poorly soluble in water, rapidly metabolised in the intestine and liver, and quickly eliminated. Without fat, piperine, or a specialised formulation, only a small amount reaches systemic circulation unchanged.

Is whole turmeric better than curcumin supplements?

They serve different purposes. Whole turmeric is best suited to food, daily culinary use, and traditional preparations. Curcumin supplements are concentrated products used when a targeted curcuminoid dose and a specific delivery system are desired.

Can turmeric be taken every day?

Turmeric can be used regularly in culinary amounts by many people, but daily supplemental curcumin is not appropriate for everyone. People taking prescription medicines, pregnant or breastfeeding women, those with gallbladder disease or bleeding risk, and anyone preparing for surgery should seek professional guidance first.

How long does turmeric take to work?

For digestive use, tolerance and comfort can often be judged sooner. For joint comfort or inflammatory support, clinical trials commonly evaluate curcumin over several weeks, often around 8 weeks or more, so consistency and the right formulation matter.

Disclaimer: Turmeric, curcumin, Trikatu, black pepper extract, and piperine supplements may not be appropriate for people with gallbladder disease, bleeding disorders, liver disease, active ulcers or reflux, pregnancy, breastfeeding, upcoming surgery, or prescription medication use. Consult a qualified Ayurvedic practitioner, doctor, pharmacist, or healthcare provider before using concentrated turmeric or curcumin supplements.

References

1. Improving Curcumin Bioavailability: Current Strategies and Future Perspectives (2021), PubMed Central
2. Lpi (lpi.oregonstate.edu)
3. Highly Bioavailable Forms of Curcumin and Promising Avenues for Curcumin-Based Research and Application: A Review (2020), PubMed Central
4. An Open Label, Randomized, Comparative Bioavailability Study of BioTurm Extract Versus Curcuma longa Extract With Piperine in Healthy Adult Volunteers (2025), PubMed
5. Cureus (cureus.com)
6. Mdpi (mdpi.com)
7. Advances and Perspectives in Curcumin Regulation of Systemic Metabolism: A Focus on Multi-Organ Mechanisms (2026), PubMed
8. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers (1998), PubMed
9. Overview of Curcumin and Piperine Effects on Glucose Metabolism: The Case of an Insulinoma Patient’s Loss of Consciousness (2023), PubMed Central
10. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 (2002), PubMed
11. Ayurvedic Pharmacopoeia of India
12. Ijrap (ijrap.net)
13. Archive (archive.org)
14. Mdpi (mdpi.com)
15. Dovepress (dovepress.com)
16. NCCIH
17. Wmic (wmic.wales.nhs.uk)
18. Medsafe (medsafe.govt.nz)
19. Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (2016), PubMed Central
20. An Investigation into the Effects of a Curcumin Extract (Curcugen(®)) on Osteoarthritis Pain of the Knee: A Randomised, Double-Blind, Placebo-Controlled Study (2021), PubMed
21. Studies on the physicochemical characteristics of heated honey, honey mixed with ghee and their food consumption pattern by rats (2010), PubMed Central